StockWatch
·

Lumino Industries Ltd Q2 FY27 Results

LUMINOQ2 FY27 Results
Filing
Result:Steady· Market: Down

Outlook: Cautiously Optimistic · Guidance: None

MetricValue (₹ Cr)vs Q1 FY27
Revenue661.4226.9%
Total Income669.2427.0%
Expenditure599.3626.9%
PBT69.8828.1%
Net Profit53.0632.1%
OPM12.77%0.82pp
NPM7.93%0.30pp
EPS2.0323.0%
View full financials

No YoY base for revenue/PAT growth is available, and standalone OPM (12.8%) and NPM (7.9%) look in-line for an industrials/cables business with no visible one-offs or deterioration.

LUMINO INDUSTRIES · Q2 FY27 · THE VERDICT

30% growth, but margins refuse to budge—the capacity ceiling explains why

Lumino delivered a textbook 30% YoY revenue beat (₹661 Cr) with order book now at ₹3,400 Cr. The catch: existing capacity at 80% utilization leaves no room to run, and despite a product mix shift toward premium HTLS and AL-59 conductors, management held EBITDA guidance at 12–13%. The call reveals why—and whether new facility ramps can unlock margin expansion.

11 Nov 2026 · 6 min read
Q2 FY27 Revenue

₹661.4 Cr

+30% YoY vs. ₹509 Cr

H1 FY27 Growth

₹1,183 Cr

+25% YoY, EBITDA 13.1%

Q2 EBITDA margin

12.8%

flat vs. Q2 FY26

PAT

₹53.1 Cr

+32% QoQ, 7.9% margin

Order book

₹3,400 Cr

₹2.2k Cr mfg (5–6m), ₹1.2k Cr EPC (3y)

Capacity utilization

80%

40k MT existing at near ceiling

On the surface, Lumino's Q2 reads like a home run: 30% revenue growth, strong order inflows (₹3,400 Cr backlog, up ₹515 Cr in October alone), and successful listing (₹500 Cr IPO, ₹337 Cr debt repaid). But lift the hood and the tension appears: margins are flat despite a deliberate shift into premium product categories—HTLS (high-temperature low-sag) conductors and AL-59 aluminum alloy cables, each commanding 1.5× conventional pricing. The company's existing 40k MT capacity is now at 80% utilization. When analysts pressed management on EBITDA expansion as new products scale, management held firm at guidance of 12–13% for manufacturing. That steadfast refusal to raise is the real story of the quarter: growth is real and order-backed, but the margin proof points are still ahead.

Revenue growth confirmed, margin quality under test

The ₹661.4 Cr revenue in Q2 checks out precisely: versus ₹509 Cr in Q2 FY26, that's a clean 30% YoY advance. Year-to-date (H1 FY27 ₹1,183 Cr) shows 25% YoY growth, and the quarterly progression from Q1 to Q2 accelerated (+27% QoQ revenue, +32% QoQ PAT). The delivery matches the call. Manufacturing represented ₹831 Cr of H1 revenue (65% conductors, 35% cables), and the EPC segment added ₹352 Cr. Profitability also landed on target: EBITDA of ₹84.6 Cr (~12.8% margin) and PAT of ₹53.1 Cr (7.9% margin) align with filed results.

Where the story tightens is on margin trajectory. EBITDA margin in Q2 FY27 was 12.8%, the same as Q2 FY26. The company shifted ~₹50 Cr in H1 revenue (4% of manufacturing) into the nascent HTLS conductor segment—a product with premium positioning and, by management's own description, "slightly better" EBITDA than conventional conductors. Yet blended manufacturing EBITDA came in at 13% in H1 (flat vs. H1 FY26). This is the gap: if new products are truly premium, why aren't blended margins expanding? Management's answer: competitive entry in AL-59 is pressuring conventional conductor volumes, so the conventional product is eroding. The new products' margin gains are offset by mix headwinds in the base business. No net uplift—yet.

Order book and capacity: the constraint made visible

The order book expansion to ₹3,400 Cr is genuine and diversified. Manufacturing orders (₹2,200 Cr, or ~65% of backlog) carry a 5–6 month execution TAT, implying roughly ₹367–440 Cr in quarterly revenue run-rate if executed smoothly. EPC orders (₹1,200 Cr, or ~35%) stretch across 3 years, with payment terms of 60% supply, 30% erection, 10% retention—a model that ties working capital. October 2026 alone added ₹386 Cr (Green Corridor Phase 3 transmission line orders), plus ₹555 Cr in L1 tenders. The pipeline is real.

But here is the hard limit: the existing Howrah facility operates at 40,000 metric tons per annum capacity, and as of H1 FY27, it is at roughly 80% effective utilization (down from 82–83% in FY26, due to a mix shift toward higher-value products that occupy the same throughput). Management flagged this bluntly: "from the existing plant, hardly there would be any major growth coming up in terms of quantity." The company has ~8,000 MT of slack on a 40k MT base. Unless order velocity slows sharply, that slack fills within weeks. Q2 delivered ₹661 Cr on ~13,800 MT volumes (a slight volume dip YoY due to mix, but similar throughput). The math is tight: to grow revenue materially in H2 FY27 without the new facility, Lumino would need average selling price (ASP) inflation or a drop in order intake—neither of which is visible in guidance or market signals.

The Ranibat facility: when it arrives, how much it changes

Lumino's escape valve is the Ranibat facility, a greenfield addition. Phase 1 (10,000 MT capacity) is slated to begin production in December 2026 or January 2027, roughly 6–7 weeks from the call. Phase 2 (another 25,000 MT) is planned for phased rollout through September 2027 and beyond, targeting a combined 75,000 MT capacity at 80%+ utilization by FY28–29. If Phase 1 ramps on schedule, H2 FY27 should see incremental production—perhaps 2,000–3,000 MT at low utilization—providing modest revenue upside but not a dramatic acceleration. The real inflection comes in FY28: if Ranibat reaches 20,000+ MT by mid-year and maintains blended EBITDA at 12–13%, then H2 FY28 revenues could push toward ₹800–900 Cr per quarter.

That is forward-looking. For now, the facility exists as a plan, not a producer. Management's confidence in the timeline is backed by in-house design and prior execution experience; however, facility ramps in India historically slip 2–4 weeks, and any slippage compresses H2 FY27 upside.

Management's key claims vs. what the data supports

Q2 FY27 revenue ₹661 Cr, 30% YoY growth

Delivered / Verified

Delivered ₹661.4 Cr; Q2 FY26 baseline ₹509 Cr = 30.0% growth

Verdict

Supported

EBITDA margin 12.8% maintained despite product mix shift to HTLS/AL-59

Delivered / Verified

H1 blended manufacturing EBITDA 13.0%, flat vs. prior year; new products ~50 bps premium but offset by conventional volume erosion

Verdict

Supported, but margin expansion not yet evident

HTLS TAM ₹5,000 Cr annually, targeting 10–15% penetration

Delivered / Verified

H1 backlog ₹50 Cr on new product; TAM is forward estimate, unverified vs. external sources

Verdict

Plausible but unproven at scale

Order book ₹3,400 Cr with 5–6 month mfg TAT, 3-year EPC TAT

Delivered / Verified

Sept 30 base ₹2,885 Cr + Oct additions ₹386 Cr + L1 tenders ₹555 Cr = ₹3,826 Cr stated, per OB bridge

Verdict

Supported; TAT splits 65% mfg, 35% EPC confirmed

New Ranibat facility adds 35k MT in phases; Phase 1 (10k MT) starts Q4 FY27 production

Delivered / Verified

Capex plan outlined; no capex amount or funding source specified; timing is Dec 2026/Jan 2027 production start

Verdict

Supported in principle; execution risk typical of facility ramps

EBITDA guidance 12–13% manufacturing, 13–14% EPC; no expansion expected

Delivered / Verified

H1 manufacturing EBITDA 13.0%, EPC 13.5%; guidance is maintenance, not uplift

Verdict

Supported; implies no margin expansion from mix or new facility in near term

What changed on this call vs. IPO listing (Sept 2026)

Order book expansion clarified. September listing disclosed ₹2,885 Cr order book; October inflows (₹386 Cr Green Corridor + ₹555 Cr L1 tenders) pushed the backlog narrative forward. This is organic growth in the pipeline, not engineering; the market took note of the October velocity.

HTLS and AL-59 strategy articulated post-listing. The IPO prospectus positioned these as growth vectors; the call put numbers on them (₹50 Cr H1 backlog, ₹5k Cr TAM, 10–15% penetration target). Investors now have a concrete track record: demand for HTLS cables exists (BHEL, BPCL, Hatech Power, IIG Infra all placed orders), and early ₹50 Cr backlog validates adoption. However, the 10–15% penetration assumption remains unproven.

Capacity plan moved from vague to phased. IPO filings mentioned capacity expansion; the Q2 call nailed down the timeline (Phase 1 Dec 2026, Phase 2 ongoing, 75k MT target by FY28–29) and gave a production start window. This removed optionality and introduced execution risk.

EBITDA margin guidance held firm despite pushback. Analysts repeatedly asked whether margin expansion should be expected as new products scaled. Management's answer: 12–13% is the sustainable range. New products are premium-priced but market adoption is gradual, conventional volumes are eroding, and competitive entry in AL-59 is real. No concessions. This is a recalibration of expectations—the market was hoping for 50–100 bps margin uplift; management signaled none.

How the street is positioned—and what the price action says

Lumino's stock closed at ₹94.16 on November 9, 2026, trading roughly 22.8% below its all-time high of ₹122 and +10.1% above its 52-week low of ₹85.51. It is trading below its 20-day simple moving average (₹95.30), implying downtrend momentum. RSI of 45.2 indicates neutral positioning (not overbought, not oversold). Volume trends are normal—no institutional stampede in or out.

Bulk and block activity reveals institutional repositioning, not conviction. Since mid-September (around IPO listing), bulk deals show a pattern of small trades by Junomoneta Finsol, Yuga Stocks, and HRTI Private Limited in the ₹104–111 range—roughly ₹10–12 per share below the current level. These are consistent with post-IPO share stabilization and profit-booking by IPO subscribers. Notably, there is no promoter insider activity in the bulk blocks and no significant FII/DII buying spikes visible in the data. The absence of insider conviction buying near the highs (when the stock was at ₹122) is a soft warning: insiders did not chase the run-up.

The 22% drawdown from ATH is not abnormal for a newly-listed infrastructure play in a neutral market, but it does signal that early enthusiasm has faded. The call's refusal to guide higher on margins likely reinforced skepticism. Valuation at ₹94 on ~5–6 month forward earnings visibility (orders ÷ TAT) is not cheap, nor is it expensive—it is fairly valued for a company showing steady execution but no step-change growth until Ranibat ramps mid-FY28.

The bull-bear ledger
  • 30% YoY revenue growth, order book expanded to ₹3.4k Cr, pipeline validated

  • New products (HTLS, AL-59) carry 1.5× premium pricing; early ₹50 Cr backlog validates demand

  • IPO (₹500 Cr) and debt repayment (₹337 Cr) improve leverage; net debt now ₹75 Cr

  • EBITDA margin guidance held flat at 12–13% despite product mix shift—no expansion expected near term

  • Existing 40k MT capacity at 80% utilization; growth limited until Ranibat ramps (Dec 2026 start, Q4 FY27 production)

  • EPC 3-year TAT orders introduce execution risk and working capital drag; government utility payment delays common (₹140 Cr WBEB collected but timing delayed)

  • Stock down 22% from ATH; no major insider buying near highs; bulk trades suggest IPO profit-booking

  • HTLS TAM (₹5k Cr) and penetration rate (10–15%) are management estimates, not market-validated; scale risk remains

Risks, ranked by how much they should concern a holder

Capacity constraint; Ranibat ramp delays into H2 FY27

High

Current 40k MT at 80% utilization leaves <8k MT slack. Q4 FY27 production start is Dec 2026/Jan 2027 estimate; any 4–6 week slip erodes H2 FY27 incremental revenue and delays margin inflection to FY28. Facility ramps in India historically slip; this is not engineered risk, it is execution risk.

Margin guidance holds at 12–13% despite new product mix shift

High

HTLS and AL-59 are positioned as premium-margin products, yet management explicitly held EBITDA guidance flat. This signals either (a) competitive intensity in new products is higher than expected, or (b) conventional volume erosion offsets new product gains. Margin inflection proof is deferred; without it, the bull case weakens. FY28 will be the test year.

HTLS TAM penetration rate (10–15%) is unproven

Medium

₹5k Cr TAM is a management estimate backed by no third-party data; 10–15% penetration (₹500–750 Cr addressable) is forward guidance. Early ₹50 Cr H1 backlog (1% of addressable) validates demand but not scale. If market adoption is slower or competitive entry erodes pricing, HTLS becomes a niche product, not a growth driver.

EPC working capital and project execution delays

Medium

₹1.2k Cr of backlog (35% of total) is EPC with 3-year TAT and 60% supply / 30% erection / 10% retention payment terms. Working capital cycle improved to 111 days but remains elevated vs. manufacturing (46 days). Any project milestone delay or government utility payment slowdown (precedent: ₹140 Cr WBEB collection took time) cascades through cash flow. H2 FY27 is heavily weighted to EPC milestone timing; execution risk is real.

Valuation offers limited margin of safety if capex/margin thesis delays

Medium

Stock at ₹94 reflects ~5–6 month forward order visibility (₹550–650 Cr quarterly mfg TAT ÷ run-rate P/E on ₹661 Cr Q2 = ~11–13x trailing earnings). If Ranibat slips or margins hold at 12% and don't expand, the stock offers no downside cushion. Drawdown from ₹122 ATH is 22%; further compression to ₹80–85 is possible if execution disappoints.

What to watch next
  • 1 · Ranibat facility production start (December 2026 target)

    The Q4 FY27 inflection hinge on this date. Any delay >2 weeks erodes H2 FY27 upside and signals execution risk. Watch for manufacturing capacity utilization beyond 80% in Q3 FY27 (would imply new facility pre-production activity). Production ramp to 5k+ MT in January 2027 would validate timeline.

  • 2 · HTLS backlog velocity and ASP realization

    H1 saw ₹50 Cr HTLS revenue. If H2 accelerates to ₹80–100 Cr (implying new orders beyond the current backlog), that signals market adoption. Watch for ASP hold near 1.5× premium; any erosion toward 1.2–1.3x would suggest competitive commoditization. EBITDA margin on HTLS orders should be monitored separately (management claims "slightly better" than conventional; Q3 segment data will clarify).

  • 3 · EPC project milestone realization and working capital conversion

    Q2 saw ₹352 Cr EPC revenue on a 3-year TAT backlog; H2 revenue will depend on milestone timing (60% supply, 30% erection). Watch for OCF conversion in H2: if PAT grows but OCF lags, it signals project payment delays (West Bengal precedent). Operating cash flow should track >60% of PAT; anything <50% is a red flag for utility payment stress.

Lumino's Q2 is a clean quarter: 30% revenue growth is real, order book is robust and order-backed, and the company has demonstrated operational discipline through listing and debt reduction. This is steady execution. It is not a step-change. The tension that defines the quarter is unflinching: margins are flat despite a deliberate shift into premium products, and the company's capacity is now at the wall. Management's refusal to raise EBITDA guidance despite the product mix tilt is the honest recalibration of expectations—margin expansion is deferred, not absent. The Ranibat facility is the next chapter; if it ramps on schedule (December 2026 start), and HTLS orders accelerate in H2, then FY28 becomes an inflection year. Until then, Lumino is a "show-me-the-capex" story.

The stock's 22% drawdown from ATH reflects this patience: the market is waiting for proof, not guessing. At ₹94, the risk-reward is fair but not compelling; the single number to track from here is manufacturing utilization in Q3 FY27 (watch for signs of capacity tightening or new facility pre-production). If utilization stays at 80–82% through October–November, Ranibat timing is on track. If it falls below 75%, that would signal demand softening or mix deflation—a yellow flag for the bull case.

Informational and educational content only. Not investment advice.